We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Can you give me his e mail address - have a request!
Dont forget Potential blockbuster
hVIVO’s flu vaccine set for phase III trials as regulators confirm mid-stage primary endpoint met
Secondary endpoints were confirmed last March and further analysis of the data has now found that the primary endpoint in symptom reduction was also met
hVIVO thinks FLU-v has the potential to be a blockbuster drug
hVIVO PLC (LON:HVO) shares zipped higher on Thursday after US regulators found that its flu vaccine did achieve its primary endpoint in last year’s mid-stage clinical trial.
The National Institute of Allergy and Infectious Diseases (NIAID) confirmed last March that FLU-v had met key secondary endpoints in symptom reduction.
READ: hVIVO builds onposition of strength in challenge trials
But the Institute said it needed more time to assess the primary endpoint as its initial analysis was based on results from a less sensitive assay, which sometimes misses the presence of influenza virus.
“The more sensitive assay, routinely utilised by NIAID to assess the presence of a virus, identified more cases of influenza infection than had originally been determined, resulting in the achievement of statistical significance,” said hVIVO executive chairman Trevor Phillips.
“We are pleased to finally be in a position to report a positive primary endpoint outcome for this phase IIb challenge study resulting from the NIAID's additional analysis of samples taken during the study.
“These final results are further verification that FLU-v is achieving measures of clinical efficacy and is now positioned to enter phase III.”
Potential blockbuster
hVIVO and its partner, SEEK Group, have a good idea of how they want to design the phase III trial which they will discuss with regulatory authorities at their upcoming meetings.
Currently, flu vaccines have to be redesigned every year as the flu virus evolves rapidly.
One of the major plus-points for FLU-v is that it offers long-lasting protection against a broad spectrum of influenza which hVIVO believes could be given to a much broader population.
“[That] would be a significant step forward, and a potential future blockbuster in terms of sales.”
By afternoon trading, hVIVO shares had leapt 36.8% higher to 39p.
-- Updates share price --
Quick facts: hVIVO PLC
Price: 16.5 GBX
LSE:HVO
Market:LSEMarket Cap:£13.79 mFollow
Sep '19Nov '19Jan '2012.51517.52022.501 000kZoom1m3m6m1yFromJul 17, 2019ToJan 17, 2020Highcharts.comMonday, Jan 6, 2020? Share price: 13.125? Volume: 265 837
View company profile
Add related topics to MyProactive
HealthPharma & BiotechhVIVO PLC
Sign up for Newsletter
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
Our professor oxford on lbc radio now
I sent Cathal Friel a email regarding the share price etc yesterday and got a reply same day.
He`s a thoroughly courteous decent bloke who certainly put my mind at ease as to future contracts and the proposed path that lays ahead for the company.
He`s not all talk since he has put his money where his mouth is and his track record is excellent as far as i can see.